Five-Time Olympic Medalist Gabby Thomas Joins Amazfit as Athlete Ambassador
13.2.2025 19:00:00 EET | Business Wire | Press release
Amazfit, a leading global smart wearables brand owned by Zepp Health (NYSE: ZEPP), is proud to announce five-time Olympic Medalist and fashion icon, Gabby Thomas, as the latest ambassador to join the brand's growing roster of elite athletes. As part of the four-year partnership, Thomas will wear Amazfit smartwatches both on the track during training and in competition, and off the track to monitor sleep and recovery. Moreover, through the Zepp app-based food log, Gabby will have easy access to nutrition-tracking as well.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250213824479/en/
Five-time Olympic Medalist and fashion icon, Gabby Thomas, is the latest ambassador to join Amazfit's growing roster of elite athletes. (Graphic: Business Wire)
As the 200m, 4x100m and 4x400m gold medalist, Thomas left the 2024 Paris Olympics as the most decorated U.S. track and field athlete at the Games. Additionally, she holds multiple Diamond League titles and took home two additional Olympic medals - 200m (bronze) and 4x100m (silver) - at the 2020 Tokyo Games. The partnership with Amazfit is Thomas’ first with a smartwatch and gives credence to the benefits data can play on athletic performance.
“I’m really excited to partner with Amazfit because, for me, the little things make all the difference,” said Thomas. “As an athlete, this is the exact type of partnership that will help me continue to get better. It's so important to have objective data on my body—whether it’s tracking my heart rate during a workout, seeing how well I’ve recovered, or understanding how much quality sleep I’m getting. Having a reliable smart wearable brand like Amazfit in my corner is a game-changer."
As part of this exciting partnership, Thomas will enhance her training by incorporating Amazfit's smart wearables analysis into her preparation and recovery to improve performance and help break future records. She will also provide insights and feedback to Amazfit’s development and design teams on product future features and styles.
"We are honored to have Gabby join the Amazfit team," said Wayne Huang, Founder & CEO, Zepp Health. "Her remarkable athletic career and passion for style align closely with our mission to unlock the limits of human potential to ‘Discover Amazing.’ Through this partnership, we will continue to empower athletes to unleash their full potential by rewriting the record books utilizing our advanced smart wearables ecosystem."
Amazfit is committed to creating products that empower holistic health and well-being, and that healthy living requires balance across four key pillars of wellness: physical fitness, sleep, mindfulness and nutrition. Amazfit’s diverse product portfolio includes Active, Cheetah and T-Rex series performance smartwatches, Helio smart ring and the Zepp App, all designed to help athletes and health enthusiasts track and enhance their holistic health. The Zepp App’s latest Food Log feature offers athletes like Thomas an unparalleled ability to bridge the gap between nutrition and fitness, ensuring peak performance and optimal recovery. Whether monitoring heart rate, tracking sleep cycles, or logging meals, Amazfit provides the insights needed to maintain a well-rounded approach to health.
Thomas joins a growing list of Amazfit athletes, including HYROX World Champions Meg Jacoby and Hunter McIntyre, Padel star Bea González and Olympians Morgan Pearson (triathlon) and Yemaneberhan "Yeman" Crippa (5k & 10k).
Explore the full range of Amazfit smart wearables and experience innovation that elevates performance, recovery, and precision at www.amazfit.com.
For more information, please visit Amazfit.com and follow us on Facebook, Instagram, Twitter and YouTube.
About Amazfit
Amazfit, a leading global smart wearable brand focused on health and fitness, is part of Zepp Health (NYSE: ZEPP), a health technology company. Offering a wide selection of smartwatches and bands, Amazfit's brand tagline "Discover Amazing", encourages individuals to break their barriers, and exceed expectations while finding joy in every moment.
Amazfit is powered by Zepp Health's proprietary health management platform that delivers cloud-based 24/7 actionable insights and guidance to help users attain their wellness goals. With outstanding craftsmanship, Amazfit smartwatches have won many design awards, including the iF Design Award and the Red Dot Design Award.
Launched in 2015, Amazfit is today embraced by millions of users. Its products are available in more than 90 countries across the Americas, EMEA, and APAC regions. For more information about Amazfit, visit www.amazfit.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250213824479/en/
Contacts
MEDIA CONTACT
Mary Thompson Woodbury
mary.woodbury@zepp.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 20263.10.2026 17:50:00 EEST | Press release
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced three-year follow-up results from the ovarian cancer cohort of its 400+ patient Phase 1b C-800-01 trial. The study evaluated botensilimab (BOT), Agenus’ multifunctional, Fc-enhanced anti-CTLA-4 antibody, in combination with balstilimab (BAL), Agenus’ anti-PD-1 antibody. The results, including three-year survival and outcomes by sensitivity to platinum-based chemotherapy and by prior treatment, were presented at the 2026 International Gynecologic Cancer Society (IGCS) Annual Global Meeting in Montréal, Canada. Among patients evaluable for efficacy, three-year overall survival was 48% (n=35), unchanged from the two-year estimate, suggesting durable clinical benefit in this population. Responses and long-term survival were observed in both platinum-sensitive and platinum-resistant or refractory disease. At the last follow-up, 25% of patients who received at least one dose of treatment (11 of 44) were alive
emnify Appoints Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer2.10.2026 18:12:00 EEST | Press release
emnify, a global leader in IoT connectivity, today announced the appointments of Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer, effective immediately. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261001902751/en/ emnify Appoints Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer The appointments follow the recent naming of Kenneth De Spiegeleire as Chief Executive Officer and Frank Stoecker as Executive Chairman of the Board. Together, these leadership changes strengthen emnify financial, operational, and commercial capabilities as the company enters its next phase of international growth. “We have proven momentum. Our ambition is to now turn it into global category leadership,” said Kenneth De Spiegeleire, CEO of emnify. “That requires sharper focus, disciplined execution, and the right capabilities in the right seats. Sacha brings financial lead
Tacton Appoints Former IFS Executive Merlin Knott as Chief Commercial Officer to Accelerate Global Growth and Scale Beyond CPQ2.10.2026 16:00:00 EEST | Press release
Tacton, a global leader in Configure, Price, Quote (CPQ) software and configuration solutions for manufacturers of complex products, today announced the appointment of Merlin Knott as Chief Commercial Officer (CCO). In this role, Knott will lead Tacton’s global commercial organization, including marketing, sales, and pre-sales, aligning the teams responsible for bringing Tacton’s solutions to market, and driving value to its customers and partners globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261002794882/en/ Merlin Knott, Chief Commercial Officer, Tacton Knott joins Tacton with decades of experience building and scaling commercial organizations across the enterprise software industry. Most recently, he held senior leadership roles at IFS, the world’s leading provider of Industrial AI software, where he led global partner and channel operations before becoming President of the company’s Enterprise Service Manageme
EDW Presents 2026 Data Quality Award to Repeat Winner Domivest2.10.2026 16:00:00 EEST | Press release
European DataWarehouse (EDW) presented its fifth annual Data Quality Award at the 2026 TSI Congress in Berlin. This year, EDW's Best Data Quality – Deal of the Year (2026) award was presented to Domivest B.V. for its transaction Domi 2023-1 B.V., recognising the firm's outstanding commitment to accurate, complete, and consistent reporting. The award is based on EDW's proprietary data quality scoring methodology, which evaluates transactions against thousands of validation rules and checks. Data quality excellence is not a one-off achievement. The fact that the same issuers continue to rank among the top performers year after year demonstrates that superior data quality is the result of sustained commitment, robust processes, and ongoing investment. "Receiving the Data Quality Award for a second time means a great deal to us. Transparent, accurate loan-level data is key to investor trust in our transactions, and we are grateful to European DataWarehouse for recognising the work our trea
ILiAD Biotechnologies Expands BPZE1 Public Health and Commercial Potential with Publication of Pediatric Phase 2b Study in The Lancet Infectious Diseases2.10.2026 15:00:00 EEST | Press release
ILiAD Biotechnologies, Inc. (ILiAD), an advanced clinical stage biotech company focused on the prevention and treatment of disease caused by Bordetella pertussis, today announced the publication of results from its Phase 2b SUPER (Stand Up to Pertussis) clinical trial in The Lancet Infectious Diseases. This randomized, double blind, placebo- and active-comparator-controlled trial demonstrated that BPZE1, a live attenuated intranasal pertussis vaccine, induced robust nasal mucosal immune responses in healthy children aged 6 through 17 years (LINK). The study demonstrated that a single intranasal dose of BPZE1 induced nasal mucosal immune responses against all Bordetella pertussis antigens tested and was well tolerated, both when administered alone and when co-administered with a tetanus-diphtheria-acellular pertussis (Tdap) booster vaccine. The multi-center Phase 2b trial enrolled 366 participants across 16 sites in the United Kingdom, Australia, and Costa Rica and included participants
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom